Recent Updates
Recently added Catalysts
SPRB Positive Sentiment

Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Wednesday, February 18, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Spruce Biosciences, a late-stage biopharmaceutical company, announced its participation in the Oppenheimer 36th Annual Healthcare Life Sciences Conference. CEO Javier Szwarcberg will engage in a fireside chat on February 25, 2026. This event underscores the company's commitment to developing therapies for neurological disorders with significant unmet needs.
Price reaction · baseline $58.245 (2026-02-17 close) · hit pre-market · clean, no other SPRB news in the window
day 0 close
-8.2%
day 1 · peak
-9.7%
day 3
-8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Spruce Biosciences is participating in a key healthcare conference.
  • The event highlights the company's focus on neurological disorders.
  • CEO Javier Szwarcberg's involvement may increase investor interest.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+42%
120-day peak, hindsight
Typical move
11.9%
average across 2 past catalysts
Cash runway
~13 mo
Low dilution risk
Lead asset
SPR001
Phase 2 · Congenital Adrenal Hyperplasia

Full Press Release Details

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc.(Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026, at 3:20 p.m. ET.
Interested parties can access the live webcasthere. An archived copy of the webcast will be available on theeventssection of the Company’s website for approximately 90 days.
About Spruce Biosciences
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need. To learn more, visitwww.sprucebio.comand follow us onX,LinkedIn,FacebookandYouTube.

Frequently Asked Questions

When is Spruce Biosciences participating in the conference?

Spruce Biosciences will participate on February 25, 2026.

Who will represent Spruce Biosciences at the conference?

CEO Javier Szwarcberg will represent the company.

What is the focus of Spruce Biosciences?

The company focuses on therapies for neurological disorders.

How can I access the conference webcast?

The live webcast can be accessed through the company's website.

ShareAdd on Google
Tags: SPRB Viatris Investor Conferences Healthcare Spruce Biosciences Oppenheimer Conference neurological disorders Javier Szwarcberg biopharmaceuticals
Last updated: Feb 18, 2026

Biotech snapshot

Cash runway
$96M liquidity · $7M/mo burn
~13 mo
Low dilution risk
Lead asset
SPR001Phase 2
Congenital Adrenal Hyperplasia →

Catalyst track record

+42%
best trade around SPRB's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for SPRB.

See every catalyst's timing & PoA →